The EMMY trial shows that early use of the SGLT2 inhibitor empagliflozin after acute myocardial infarction (MI) improves natriuretic peptide levels and markers of cardiac function and structure supporting the use of empagliflozin in HF related to a recent MI. Here, SLC5A2 is linked to myocardial infarction.